Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044).
- Citation:
- Am J Clin Oncol vol 30 (5) 507-13
- Year:
- 2007
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Pharmas:
- Grants:
- CA-25224, CA-35101, CA-35103, CA-35195, CA-35267, CA-35269, CA-35415, CA-35431, CA-35448, CA-37404, CA-52352, CA-60276
- Corr. Author:
- Authors:
- Aminah Jatoi James A Martenson Nathan R Foster Howard L McLeod Bradley S Lair Frank Nichols Loren K Tschetter Dennis F Moore Tom R Fitch Steven R Alberts
- Networks:
- Study
- NCCTG-N0044
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Adult, Antineoplastic Combined Chemotherapy Protocols, Area Under Curve, Carboplatin, Combined Modality Therapy, Esophageal Neoplasms, Female, Fluorouracil, Humans, Male, Neoplasm Staging, Paclitaxel, Patient Selection, Radiotherapy, Recurrence, Survival Analysis, Survivors, Time Factors